Urban Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History

Urban Wealth Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$0	Buy	+4	New	+$369	﹤0.01%	359

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

EVM

Eaton Vance Management Boston, Massachusetts $67.5B AUM 11.44% 1-Year Est. Return

Urban Wealth Management's NBIX Position: Q2 2022 in Review

Urban Wealth Management opened a new position in Neurocrine Biosciences (NBIX) in Q2 2022: 4 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #359 among its holdings.

437 funds tracked by Wall St. Rank hold NBIX as of Q2 2022.

Urban Wealth Management held 4 shares of Neurocrine Biosciences worth $0 as of Q2 2022.
Neurocrine Biosciences was a new Urban Wealth Management position in Q2 2022.
Neurocrine Biosciences made up ﹤0.01% of Urban Wealth Management's portfolio in Q2 2022, its #359 holding.
437 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2022.

Based on Urban Wealth Management's 13F filing for Q2 2022, filed 22 Jul 2022.